Sustainable approaches for drug repurposing in rare diseases: recommendations from the IRDiRC Task Force

Abstract

Drug repurposing represents a real opportunity to address unmet needs and improve the lives of rare disease patients. It is often presented as a faster, safer and cheaper path for bringing drugs into new indications. However, several economic, regulatory and scientific barriers can impede the successful repurposing of drugs for rare diseases. The International Rare Diseases Research Consortium (IRDiRC) set up the Task Force on Sustainable Models in Drug Repurposing with the objective of identifying key factors for achieving sustainable repurposing approaches in rare diseases.

In order to help inform expert opinion, the Task Force investigated six cases of medicinal products repurposed into new rare indications and four cases of ongoing development programs. A questionnaire addressing the major steps of the repurposing approach was developed by the Task Force and sent to contact points of the organizations. In addition, interviews were conducted with the relevant organization representatives to conduct a deeper dive into the sustainability of the repurposing approach for each of the selected cases.

Based on the collective experience of the members of the Task Force and the output from the questionnaires/interviews, we have identified ten key factors that should be considered by those embarking on repurposing projects. These factors include the identification of unmet patient needs and partnership with patients, collection of evidence concerning disease prevalence, patient numbers, drug pharmacology and disease etiology, drug industrial property status, off-label or compounding use, data from past clinical studies and needs for extended non-clinical and clinical studies. The development of a collaborative funding framework and early discussion with regulators and payers are additional factors to implement early in the development of sustainable drug repurposing projects.

Keywords

Drug repurposing / rare diseases / orphan drugs / sustainable approaches / medicines development / IRDiRC

References

[1] Bellera CL,Gantner ME.Can drug repurposing strategies be the solution to the COVID-19 crisis?.Expert Opin Drug Discov2021;16:605-12

[2] Venkatesan P.Repurposing drugs for treatment of COVID-19.Lancet Respir Med2021;9:e63 PMCID:PMC8175045

[3] Giannuzzi V,Landi A.Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.Orphanet J Rare Dis2017;12:64 PMCID:PMC5376695

[4] Nguengang Wakap S,Olry A.Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database.Eur J Hum Genet2020;28:165-73 PMCID:PMC6974615

[5] Southall NT,Lau LPL.IRDiRC Data Mining and Repurposing Task ForceThe use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force.Orphanet J Rare Dis2019;14:225 PMCID:PMC6794821

[6] Breckenridge A.Overcoming the legal and regulatory barriers to drug repurposing.Nat Rev Drug Discov2019;18:1-2

[7] Begley CG,Baell J.Drug repurposing: misconceptions, challenges, and opportunities for academic researchers.Sci Transl Med2021;13:eabd5524

[8] Pushpakom S,Eyers PA.Drug repurposing: progress, challenges and recommendations.Nat Rev Drug Discov2019;18:41-58

[9] Member States, National Competent Authorities; EU Innovation Offices. Proposal for a framework to support not-for-profit organisations and academia (institutions and individuals) in drug repurposing. Available from: https://ec.europa.eu/health/system/files/2021-10/pharm773_repurposing_annex_en_0.pdf [Last accessed on 11 Apr 2023]

[10] Miller KL.Investigating the landscape of US orphan product approvals.Orphanet J Rare Dis2018;13:183 PMCID:PMC6198498

[11] U.S. Food and Drug Administration. Search orphan drug designations and approvals. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ [Last accessed on 11 Apr 2023]

[12] Orphanet Inserm US14. Lists of medicinal products for rare diseases in Europe. Available from: https://www.myobase.org/doc_num.php?explnum_id=10705 [Last accessed on 11 Apr 2023]

[13] Postema PG,Arbelo E.Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine.Eur Heart J2020;41:614-7

[14] Simoens S,Cassiman D.PHP15 What price do we pay for repurposing medicines for rare diseases?.Value in Health2012;15:A15-6

[15] WHO/EURO. Repurposing of medicines in oncology - the underrated champion of sustainable innovation. Available from: https://apps.who.int/iris/bitstream/handle/10665/342567/WHO-EURO-2021-2807-42565-59178-eng.pdf?sequence=1&isAllowed=y [Last accessed on 11 Apr 2023]

[16] Aartsma-Rus A,O’Reilly D.The role of patient involvement when developing therapies.Nucleic Acid Ther2022;32:118-22 PMCID:PMC9058870

[17] Cavaller-Bellaubi M,Teixeira B.Sustaining meaningful patient engagement across the lifecycle of medicines: a roadmap for action.Ther Innov Regul Sci2021;55:936-53 PMCID:PMC8108434

[18] Hoos A,Boutin M.Partnering with patients in the development and lifecycle of medicines: a call for action.Ther Innov Regul Sci2015;49:929-39 PMCID:PMC4616907

[19] REPO4EU. The Euro-global platform for mechanism-based drug repurposing. Available from: https://repo4.eu/ [Last accessed on 11 Apr 2023]

[20] REMEDi4ALL. The European Platform for medicines repurposing. Available from: https://remedi4all.org/ [Last accessed on 11 Apr 2023]

[21] European Commission. Horizon Europe work programme 2021-2022. Available from: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-4-health_horizon-2021-2022_en.pdf [Last accessed on 11 Apr 2023]

[22] U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER). Guidance for industry applications covered by section 505(b)(2). Available from: https://www.fda.gov/media/72419/download [Last accessed on 11 Apr 2023]

[23] Hechtelt Jonker A,Gabaldo M.Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook.Nat Rev Drug Discov2020;19:495-6

[24] IRDIRC. Drug Repurposing guidebook. Available from: https://irdirc.org/drug-repurposing-guidebook/ [Last accessed on 11 Apr 2023]

[25] Asker-Hagelberg C,Bouygues C.Repurposing of medicines in the EU: launch of a pilot framework.Front Med (Lausanne)2021;8:817663 PMCID:PMC8784735

[26] Hivert V,O’connor D.IRDiRC: 1000 new rare diseases treatments by 2027, identifying and bringing forward strategic actions.Rare Dis Orphan Drugs J2022;1:3

[27] National Institute of Allergy and Infectious Diseases (NIAID). NOT-AI-16-052: Notice of NIAID’s participation in PA-16-183 “limited competition: Rare Diseases Clinical Research Network (RDCRN) Project supplements for clinical trials to repurpose drugs in collaboration with e-rare awardees (Admin Supp)”. Available from: https://grants.nih.gov/grants/guide/notice-files/NOT-AI-16-052.html [Last accessed on 11 Apr 2023]

[28] NOT-TR-19-029: NCATS announces the cures acceleration network review board workshop: repurposing off-patent drugs: research & regulatory challenges. Available from: https://grants.nih.gov/grants/guide/notice-files/NOT-TR-19-029.html [Last accessed on 11 Apr 2023]National Center for Advancing Translational Sciences (NCATS).

[29] ERA-LEARN. E-Rare 3 call for proposals 2016 (JTC 2016): clinical research for new therapeutic uses of already existing molecules (repurposing) in rare diseases. Available from: https://www.era-learn.eu/network-information/networks/e-rare-3/e-rare-3-call-for-proposals-2016-jtc-2016-clinical-research-for-new-therapeutic-uses-of-already-existing-molecules-repurposing-in-rare-diseases [Last accessed on 11 Apr 2023]

[30] European Medicines Agency. Clinical trials regulation. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials/clinical-trials-regulation [Last accessed on 11 Apr 2023]

[31] PARADIGM. Patient engagement toolbox. Available from: https://imi-paradigm.eu/petoolbox/ [Last accessed on 11 Apr 2023]

[32] U.S. Food Drug Administration. Repurposing off-patent drugs: research & regulatory challenges. Available from: https://www.fda.gov/drugs/news-events-human-drugs/repurposing-patent-drugs-research-regulatory-challenges-12052019-12062019 [Last accessed on 11 Apr 2023]

[33] Reagan-Udall Foundation for the FDA. Repurposing off-patent drugs: research & regulatory challenges. Available from: https://reaganudall.salsalabs.org/repurposingoffpatentdrugsworkshop/index.html [Last accessed on 11 Apr 2023]

[34] European Medicines Agency. Repurposing of authorised medicines: pilot to support not-for-profit organisations and academia. Available from: https://www.ema.europa.eu/en/news/repurposing-authorised-medicines-pilot-support-not-profit-organisations-academia [Last accessed on 11 Apr 2023]

[35] IRDiRC. Shared molecular etiologies underlying multiple rare diseases. Available from: https://irdirc.org/shared-molecular-etiologies/ [Last accessed on 11 Apr 2023]

[36] IRDiRC. Pluto Project. Disregarded rare diseases. Available from: https://irdirc.org/pluto-project-disregarded-rare-diseases/ [Last accessed on 11 Apr 2023]

[37] IRDiRC. Vision & goals. Available from: https://irdirc.org/about-us/vision-goals/ [Last accessed on 11 Apr 2023]